Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 13/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3020043 | 0.91 | KDR (0.41) | KDRFGFR3FLT3GABRG2GABRB3 | |
| SCHEMBL3022577 | 0.90 | KDR (0.40) | KDRFGFR3FLT3HTR1AGABRG2 | |
| SCHEMBL3015835 | 0.87 | KDR (0.40) | KDRFGFR3FLT3HTR1AGABRG2 | |
| SCHEMBL3026450 | 0.86 | KDR (0.39) | KDRFGFR3HTR1A | |
| SCHEMBL3022581 | 0.83 | KDR (0.41) | KDRFGFR3FLT3GABRG2GABRB3 | |
| SCHEMBL3033317 | 0.83 | KDR (0.58) | KDRFGFR3FLT3GABRG2GABRB3 | |
| SCHEMBL3032130 | 0.82 | FLT3 (0.47) | KDRFGFR3FLT3GABRG2GABRB3 | |
| SCHEMBL3015840 | 0.81 | KDR (0.40) | KDRFGFR3FLT3 | |
| SCHEMBL3020624 | 0.80 | KDR (0.46) | KDRFGFR3FLT3GABRG2GABRB3 | |
| SCHEMBL3022546 | 0.80 | KDR (0.49) | KDRFGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367662-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-02-05 | — | — | US | disclosed |
| EP-2212323-B1 | IMIDAZO [1,2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | NOVARTIS AG (CH) | 2012-08-15 | — | — | EP | disclosed |
| US-20100210641-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-08-19 | — | — | US | disclosed |
| EP-2212323-A2 | IMIDAZO [1,2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009050183-A2 | IMIDAZO [1, 2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210641-A1 | Organic Compounds | ALK, ACVR1, ACVRL1 | KDR 372/4885FGFR3 32/4885FLT3 4384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.